Precigen Inc(PGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 7:30 PM ET (Korea 9/16 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.1 | Insider Own | 54.16% | Shs Outstand | 358.0M | Perf Week | 1.89% |
| Market Cap | 2.51B | Forward P/E | 10.24 | EPS next Y | 388.09% | Insider Trans | -3.05% | Shs Float | 164.1M | Perf Month | 14.75% |
| Enterprise Value | 2.57B | PEG | - | EPS next Q | 0.05 | Inst Own | 39.72% | Short Float | 25.7% | Perf Quarter | 45.83% |
| Income | -0.34B | P/S | 29.24 | EPS this Y | 110.22% | Inst Trans | 2.62% | Short Ratio | 8.57 | Perf Half Y | 99.43% |
| Sales | 0.09B | P/B | 57.51 | EPS next 5Y | - | ROA | -115.88% | Short Interest | 42.18M | Perf YTD | 67.46% |
| Book/sh | 0.12 | P/C | 65.59 | EPS past 3/5Y | -60.61% -6.02% | ROE | -837.08% | 52W High | -9.27% ($7.72) | Perf Year | 94.99% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | -28.87% -37.7% | ROIC | -111.95% | 52W Low | 134.11% ($2.99) | Perf 3Y | 369.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -154.83% | Gross Margin | 89.19% | Volatility(W/M) | 3.4% 4.81% | Perf 5Y | 27.97% |
| Dividend TTM | - | EV/Sales | 29.94 | Sales Y/Y TTM | 1875.05% | Oper. Margin | -46.08% | ATR (14) | 0.32 | Perf 10Y | -74.24% |
| Dividend Ex-Date | - | Quick Ratio | 3.89 | EPS Q/Q | 153.95% | Profit Margin | -392.81% | RSI (14) | 55.41 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.58 | Sales Q/Q | 6322.66% | SMA20 | -0.46% ($7.03) | Beta | 0.95 | Target Price | $14.5 |
| Payout | - | Debt/Eq | 2.26 | Earnings | 2026/8/4 | SMA50 | 10.3% ($6.35) | Rel Volume | 0.56 | Prev Close | $6.85 |
| Employees | 160 | LT Debt/Eq | 2.23 | EPS/Sales Surpr. | 513.22% 96.47% | SMA200 | 48.07% ($4.73) | Avg Volume(3M) | 4.92M | Price | $7 |
| IPO | 2013/8/8 | Option/Short | Yes/Yes | Trades | 15524 | Volume | 2,767,623 | Change | 2.19% |
Company
PGEN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Precigen (PGEN) is a US biotech company developing differentiated novel therapeutics in immuno-oncology, autoimmune, and infectious disease areas, based on a gene and cell therapy platform. Having secured its first FDA-approved gene therapy for recurrent respiratory papillomatosis, the company is transitioning from the clinical stage to the commercial stage.
Over the past 1 year, on the higher side
9% below its 1-year high.
PGEN has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +110.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +369.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 39.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBC 0.01%
FYC 0.00%
XBI 0.00%
LABU 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $3B.
PGEN $3B PER -
VRTX $130B PER 29.9
REGN $80B PER 19.1
ARGX $61B PER 37.3
FAQ
What kind of company is PGEN?
PGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PGEN?
The market cap of PGEN is approximately $2.5B, ranking 1,916 within its sector.
What is the 52-week high and low for PGEN?
PGEN has recorded a 52-week high of $7.72 and a low of $2.99.
